Low Back Pain – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Low Back Pain – Pipeline Review, H1 2018’, provides an overview of the Low Back Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Low Back Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Low Back Pain

– The report reviews pipeline therapeutics for Low Back Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Low Back Pain therapeutics and enlists all their major and minor projects

– The report assesses Low Back Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Low Back Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Low Back Pain

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Low Back Pain pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ache Laboratorios Farmaceuticos SA

Adynxx Inc

AnGes Inc

Array BioPharma Inc

Axsome Therapeutics Inc

Boehringer Ingelheim GmbH

Daewon Pharm Co Ltd

Egalet Corp

Frontier Biotechnologies Inc

Gador SA

Grunenthal GmbH

Hisamitsu Pharmaceutical Co Inc

Immune Pharmaceuticals Inc

Indena SpA

Inspyr Therapeutics Inc

MD Biosciences GmbH

Mesoblast Ltd

Nektar Therapeutics

Orion Corporation

Pacira Pharmaceuticals Inc

Pfizer Inc

Stayble Therapeutics AB

Therapix Biosciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Low Back Pain Overview

Low Back Pain Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Low Back Pain Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Low Back Pain Companies Involved in Therapeutics Development

Ache Laboratorios Farmaceuticos SA

Adynxx Inc

AnGes Inc

Array BioPharma Inc

Axsome Therapeutics Inc

Boehringer Ingelheim GmbH

Daewon Pharm Co Ltd

Egalet Corp

Frontier Biotechnologies Inc

Gador SA

Grunenthal GmbH

Hisamitsu Pharmaceutical Co Inc

Immune Pharmaceuticals Inc

Indena SpA

Inspyr Therapeutics Inc

MD Biosciences GmbH

Mesoblast Ltd

Nektar Therapeutics

Orion Corporation

Pacira Pharmaceuticals Inc

Pfizer Inc

Stayble Therapeutics AB

Therapix Biosciences Ltd

Low Back Pain Drug Profiles

(acetaminophen + caffeine + diclofenac sodium + orphenadrine) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(clonidine + naltrexone) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diclofenac epolamine + lidocaine) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(eperisone + pelubiprofen) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(loxoprofen + methocarbamol) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aceclofenac + eperisone SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-0101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARRY-954 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AYX-2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bupivacaine ER Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cebranopadol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexmedetomidine hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol + palmidrol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HP-3150 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDN-5243 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IG-8801 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MD-22 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MPC-06ID Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NKTR-181 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxycodone hydrochloride ER Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize ADORA2A for Low Back Pain, Arthritis Pain and Inflammation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STA-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STA-363 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tanezumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zoledronate disodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Low Back Pain Dormant Projects

Low Back Pain Discontinued Products

Low Back Pain Product Development Milestones

Featured News & Press Releases

Mar 29, 2018: Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment

Mar 20, 2018: Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain

Feb 27, 2018: AnGes Announces First Patient Treated with NF-kappa B Decoy in Phase Ib Study to Treat Discogenic Low Back Pain

Feb 20, 2018: Egalet Announces Issuance of New U.S. Patent for Guardian Technology

Nov 28, 2017: Egalet Announces Positive Top-Line Results from Phase 3 Study Evaluating Efficacy and Safety of Egalet-002 in Patients with Moderate-to-Severe Chronic Low Back Pain

Sep 25, 2017: Mesoblast Provides Update on lead product candidate MPC-06-ID at Global Healthcare Conferences

Jun 13, 2017: Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab

Apr 25, 2017: AnGes Announces FDA Clearance of Investigational New Drug Application for NF-kappaB decoy oligo DNA to treat discogenic lower back pain

Mar 24, 2017: AnGes: Investigational New Drug (IND) Application Submitted to the FDA

Mar 20, 2017: NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain

Mar 15, 2017: Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection of Mesoblast’s Cell Therapy

Aug 01, 2016: MesoblastS Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science

Jul 25, 2016: Hisamitsu Pharmaceutical Announces the results of Phase II clinical study of HP-3150 in Japan for “Lower back pain” (an analgesic transdermal drug containing NSAIDs)

Jun 22, 2016: Frontier Biotech Reports Primary Endpoint Met in Phase 2 Trial of AB001 In Chronic Low Back Pain

Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Low Back Pain, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Low Back Pain Pipeline by Ache Laboratorios Farmaceuticos SA, H1 2018

Low Back Pain Pipeline by Adynxx Inc, H1 2018

Low Back Pain Pipeline by AnGes Inc, H1 2018

Low Back Pain Pipeline by Array BioPharma Inc, H1 2018

Low Back Pain Pipeline by Axsome Therapeutics Inc, H1 2018

Low Back Pain Pipeline by Boehringer Ingelheim GmbH, H1 2018

Low Back Pain Pipeline by Daewon Pharm Co Ltd, H1 2018

Low Back Pain Pipeline by Egalet Corp, H1 2018

Low Back Pain Pipeline by Frontier Biotechnologies Inc, H1 2018

Low Back Pain Pipeline by Gador SA, H1 2018

Low Back Pain Pipeline by Grunenthal GmbH, H1 2018

Low Back Pain Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2018

Low Back Pain Pipeline by Immune Pharmaceuticals Inc, H1 2018

Low Back Pain Pipeline by Indena SpA, H1 2018

Low Back Pain Pipeline by Inspyr Therapeutics Inc, H1 2018

Low Back Pain Pipeline by MD Biosciences GmbH, H1 2018

Low Back Pain Pipeline by Mesoblast Ltd, H1 2018

Low Back Pain Pipeline by Nektar Therapeutics, H1 2018

Low Back Pain Pipeline by Orion Corporation, H1 2018

Low Back Pain Pipeline by Pacira Pharmaceuticals Inc, H1 2018

Low Back Pain Pipeline by Pfizer Inc, H1 2018

Low Back Pain Pipeline by Stayble Therapeutics AB, H1 2018

Low Back Pain Pipeline by Therapix Biosciences Ltd, H1 2018

Low Back Pain Dormant Projects, H1 2018

Low Back Pain Dormant Projects, H1 2018 (Contd..1), H1 2018

Low Back Pain Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Low Back Pain, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports